{
    "nctId": "NCT00541086",
    "briefTitle": "Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery",
    "officialTitle": "A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 3697,
    "primaryOutcomeMeasure": "Disease-free survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast cancer completely removed by surgery\n\n  * Any T, any N\n  * No recurrent or metastatic disease\n* Estrogen or progesterone receptor-positive disease in primary tumor, as defined by 1 of the following:\n\n  * At least 10% of tumor cells positive by immunohistochemistry\n  * At least 10 fmol/mg cytosol protein by ligand binding assay\n* Patients with HER-2/neu positive tumors are eligible provided they receive trastuzumab (Herceptin\u00ae) according to the registered schedule\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Postmenopausal, defined by \u2265 1 of the following:\n\n  * Age \u2265 60 years\n  * Age 45-59 and satisfying 1 or more of the following criteria:\n\n    * Amenorrhea for \u2265 12 months AND intact uterus\n    * Amenorrhea (secondary to hysterectomy, hormone replacement therapy (HRT), or chemotherapy) for \\< 12 months AND follicle-stimulating hormone within the postmenopausal range\n  * Underwent prior bilateral oophorectomy at any age \\>18 years\n* No concurrent illness that contraindicates adjuvant endocrine treatment\n* No other invasive breast cancer or invasive malignancy within the past 10 years, except adequately cone-biopsied squamous cell or basal cell skin cancer or carcinoma in situ of the cervix\n* No concurrent disease that would place the patient at unusual risk\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Adjuvant or neoadjuvant chemotherapy must be completed prior to study entry\n* At least 1 month since prior and no concurrent HRT\n* More than 30 days since prior systemic investigational drugs\n* No prior tamoxifen as part of any breast cancer prevention study\n* Prior or concurrent locoregional radiotherapy allowed\n* No other concurrent experimental drugs\n* No concurrent bisphosphonates, unless indicated as treatment for osteoporosis",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}